Anima Biotech built BioGPU, the runtime for AI in biology. BioGPU enables AI agents to reason inside biology through massive parallel visual biology experiments. At the core of BioGPU is the BioGPU Runtime, which executes visual biology experiments at scale inside cells and generates thousands of Visual Biology Tokens that capture pathway activity, cellular states, regulatory mechanisms, and biological processes. The BioGPU Agent connects to the BioGPU Runtime and uses these Visual Biology Tokens to investigate biological questions and progressively increase the resolution of disease biology. This creates a new way for AI to interact with biology: not by reasoning only from existing knowledge, but by learning directly from biology inside cells. As Biology Resolution Loops iterate, disease networks become increasingly resolved, enabling a deeper understanding of how pathways drive disease, what targets do, how they are regulated, and how compounds alter biology. BioGPU enables the experimental resolution of pathways, targets, and compounds, helping scientists understand the causal biology driving disease, the function of targets, and the effects of compounds. Our BioGPU technology has been applied across more than 20 discovery programs and strategic collaborations with AbbVie, Takeda, and Lilly.
Looking for a particular Anima Biotech employee's phone or email?
The Anima Biotech annual revenue was $18.8 million in 2026.
Iris Alroy is the Co-Founder and Chief Scientific Officer of Anima Biotech.
51 people are employed at Anima Biotech.
Anima Biotech is based in Bernardsville, New Jersey.
The NAICS codes for Anima Biotech are [54, 541714, 541, 5417, 54171].
The SIC codes for Anima Biotech are [87, 873].